SEARCH:   Advanced

Blood, 15 October 2007, Vol. 110, No. 8, pp. 2846-2854. Prepublished online as a Blood First Edition Paper on July 3, 2007; DOI 10.1182/blood-2006-10-051771. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-10-051771v1 110/8/2846    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Galicier, L. Articles by Oksenhendler, E. Search for Related Content PubMed PubMed Citation Articles by Galicier, L. Articles by Oksenhendler, E. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study Lionel Galicier1, Claire Fieschi1, Raphael Borie1, Véronique Meignin2, Marie-Thérèse Daniel3, Laurence Gérard1, and Eric Oksenhendler1 Departments of1 Clinical Immunology 2 Pathology, and 3 Cytology and Molecular Hematology, Hôpital St Louis, Assistance Publique–Hôpitaux de Paris, Paris, France Prognosis of acquired immunodeficiency syndrome (AIDS)–related non-Hodgkin lymphoma has improved since the introduction of highly active antiretroviral therapy. Burkitt lymphomas (BLs) still have poor outcome in patients with bone marrow (BM) or central nervous system (CNS) involvement when treated with standard-dose chemotherapy. We have prospectively evaluated the LMB86 regimen in 63 human immunodeficiency virus (HIV)–infected patients with stage IV (BM and/or CNS involvement) BL consecutively recruited between November 1992 and January 2006. At BL diagnosis, the median CD4 cell count was 239 x 106/L (range, 16-1188 x 106/L). BM and CNS involvement were present in 55 (80%) and 48 (76%) patients, respectively. Forty-four patients (70%) achieved complete response. Seven treatment-related deaths occurred and all patients experienced severe BM toxicity. With a median follow-up of 66 months (range, 6-165 months), 11 patients relapsed. The estimate 2-year overall survival and disease-free survival were 47.1% (95% CI, 34-59.1) and 67.8% (95% CI, 51-80), respectively. We identified 2 poor prognosis factors: low CD4 count and ECOG more than 2. Patients with 0 or 1 factor had good outcome (2-year survival: 60%) contrasting with patients with 2 factors (2-year survival: 12%). We conclude that LMB86 regimen is highly effective in advanced HIV-related BL and should be proposed for patients with CD4 count higher than 200 x 106/L or ECOG of 2 or less. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J.-P. Spano, D. Costagliola, C. Katlama, N. Mounier, E. Oksenhendler, and D. Khayat AIDS-Related Malignancies: State of the Art and Therapeutic Challenges J. Clin. Oncol., October 10, 2008; 26(29): 4834 - 4842. [Abstract] [Full Text] [PDF] J.-M. Ribera and J.-T. Navarro Human immunodeficiency virus-related non-Hodgkin's lymphoma Haematologica, August 1, 2008; 93(8): 1129 - 1132. [Full Text] [PDF] A. S. Perkins and J. W. Friedberg Burkitt Lymphoma in Adults Hematology, January 1, 2008; 2008(1): 341 - 348. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020